Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 11, Issue Suppl 1
340 TGFβDNRII genetically-engineered TIL: characterizing final drug product from a phase I clinical trial
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
Regular and Young Investigator Award Abstracts
Cellular Therapies
340 TGFβDNRII genetically-engineered TIL: characterizing final drug product from a phase I clinical trial
Online download statistics by month:
Online download statistics by month: November 2023 to June 2025
Abstract
Full
Pdf
Nov 2023
198
0
13
Dec 2023
47
0
8
Jan 2024
22
0
0
Feb 2024
32
0
2
Mar 2024
36
0
2
Apr 2024
38
0
3
May 2024
54
0
6
Jun 2024
24
0
14
Jul 2024
38
0
4
Aug 2024
14
0
2
Sep 2024
24
0
2
Oct 2024
13
0
5
Nov 2024
22
0
7
Dec 2024
23
0
4
Jan 2025
18
0
8
Feb 2025
2
0
1
Mar 2025
0
0
4
Apr 2025
1
0
3
May 2025
0
0
10
Jun 2025
0
0
2
Total
606
0
100
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
PDF